Skip to main content

Table 4 Multivariate analysis in the whole population

From: Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT

 

RI

NRM

LFS

OS

 

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Year of AHSCT

1 (0.98–1.03)

0.94

1 (0.94–1.06)

0.99

1 (0.98–1.02)

0.85

1 (0.97–1.02)

0.72

TCP-ALL vs. BCP-ALL

0.7 (0.54–0.9)

0.006

1.26 (0.7–2.26)

0.45

0.76 (0.61–0.96)

0.023

0.75 (0.58–0.96)

0.024

Age (per 10 years)

1.05 (0.96–1.14)

0.3

1.49 (1.23–1.79)

< 0.0001

1.1 (1.02–1.19)

0.011

1.17 (1.08–1.28)

0.0001

Female vs. male patient

0.89 (0.69–1.16)

0.39

0.84 (0.46–1.53)

0.57

0.88 (0.69–1.11)

0.28

0.91 (0.71–1.18)

0.49

TBI- vs. CT-based conditioning

0.96 (0.72–1.27)

0.77

0.6 (0.31–1.13)

0.11

0.9 (0.7–1.17)

0.44

0.92 (0.7–1.21)

0.55

Time from diagnosis to AHSCT (per month)

0.95 (0.9–0.99)

0.018

0.95 (0.86–1.05)

0.35

0.95 (0.91–0.99)

0.01

0.94 (0.9–0.99)

0.013

  1. RI relapse incidence, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, ALL acute lymphoblastic leukemia, BCP-ALL B-cell precursor ALL, TCP-ALL T-cell precursor ALL, TBI total body irradiation, CT chemotherapy, AHSCT autologous hematopoietic stem cell transplantation, HR hazard ratio, CI confidence interval, vs. versus